#antisense RNA

[willowreader]

Continuous presence of SARS-CoV-2 RNA, particularly antisense ORF1ab RNA, suggests the virus may remain active long after initial infection. This could explain some of the persistent symptoms of long COVID

If you would like an analysis of this study please read the twitter thread below.

[health-views-updates]

Global Antisense and RNAi therapeutics Market Share, Industry Trends, Regional Analysis, Growth Factors and Competitive Analysis by Players

The global antisense and RNA interference therapeutics market is poised for remarkable growth, with projections indicating the market will expand from USD 4.15 billion in 2023 to USD 18.48 billion by 2032. This growth reflects a robust compound annual growth rate (CAGR) of 18.05% over the forecast period from 2024 to 2032, driven by advances in genetic therapies and the rising prevalence of chronic diseases.

Antisense and RNAi therapeutics represent cutting-edge biotechnological approaches that target and regulate gene expression at the molecular level, offering innovative treatments for a range of genetic disorders, cancers, and neurodegenerative diseases. By silencing or modulating the expression of disease-causing genes, these therapies have the potential to address conditions previously considered untreatable.

Key Drivers of Market Growth

Rising Prevalence of Genetic and Chronic Diseases: The increasing incidence of genetic disorders, neurodegenerative diseases, and cancer has led to a surge in demand for novel therapeutic approaches. Antisense and RNAi therapies offer targeted treatment options by selectively silencing disease-related genes. Conditions such as Huntington's disease, Duchenne muscular dystrophy, and various cancers have become key targets for these innovative therapies, contributing to the expansion of the market.

Advancements in Drug Development and Delivery Technologies: Recent technological advancements in RNA delivery systems, such as lipid nanoparticles and conjugated oligonucleotides, have significantly improved the stability, efficacy, and safety of antisense and RNAi therapeutics. These innovations have led to a more streamlined drug development process and increased the number of promising therapies reaching clinical trials. As more RNA-based treatments are approved and commercialized, the market is expected to experience accelerated growth.

Growing Investment in Biotechnology and Genomic Medicine: Substantial investments from both public and private sectors in biotechnology and genomic medicine are playing a crucial role in the market’s expansion. Governments, research institutions, and pharmaceutical companies are increasingly focusing on gene therapies and precision medicine to address complex diseases. These investments are fueling research and development in antisense and RNAi therapeutics, paving the way for more clinical applications and breakthroughs.

Favorable Regulatory Landscape: Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have been supportive of antisense and RNAi therapeutics, expediting approvals for novel drugs targeting rare diseases. This favorable regulatory environment is encouraging pharmaceutical companies to invest in these technologies, contributing to the accelerated commercialization of therapies.

Access Free Sample Report: https://www.snsinsider.com/sample-request/4493

Challenges and Opportunities

Despite the significant growth potential, challenges persist in the antisense and RNAi therapeutics market. Issues related to off-target effects, delivery efficiency, and the high cost of treatment development continue to pose hurdles. However, ongoing research aimed at improving RNA delivery systems and reducing side effects is expected to mitigate these challenges, unlocking further market potential.

Additionally, the shift toward personalized medicine, where therapies are tailored to the genetic profile of individual patients, presents a significant opportunity for the antisense and RNAi market. Personalized approaches allow for more targeted and effective treatments, particularly in oncology and rare genetic disorders, positioning the market for sustained growth.

Regional Insights

North America leads the global antisense and RNAi therapeutics market, owing to its strong biotechnology sector, cutting-edge research facilities, and favorable regulatory environment. The region’s dominance is bolstered by the presence of key market players, ongoing clinical trials, and increasing healthcare expenditure.

Europe is also a significant contributor to market growth, driven by rising government support for biotechnology research and a growing focus on gene therapy. Meanwhile, the Asia-Pacific region is expected to witness the fastest growth during the forecast period, spurred by expanding healthcare infrastructure, increasing investments in biotechnology, and a rising focus on precision medicine in countries like China, Japan, and South Korea.

Future Outlook

The future of the antisense and RNAi therapeutics market looks promising, with continued advancements in genetic medicine, personalized therapies, and RNA delivery technologies. With several RNA-based treatments already approved and more in the pipeline, the market is set to experience robust growth in the coming years. The projected CAGR of 18.05% between 2024 and 2032 signals strong investor confidence and significant opportunities for innovation.

In conclusion, the antisense and RNAi therapeutics market is on the cusp of a major expansion, driven by advances in gene-silencing technologies, increasing demand for targeted therapies, and strong industry support. From a valuation of USD 4.15 billion in 2023, the market is expected to reach USD 18.48 billion by 2032, revolutionizing the landscape of therapeutic development for genetic and chronic diseases.

Other Trending Reports

Smart Fertility Tracker Market Size

Venous Thromboembolism Treatment Market Size

Automated Liquid Handling Technologies Market Size

Digestive Health Supplements Market Size

[veliterbio]

Why Are Custom Oligos Essential for Targeted Therapeutics?

Because they allow for exact manipulations of gene expression and molecular pathways, custom oligos are crucial for targeted treatments. Through the creation of customized oligonucleotides based on particular genetic targets, scientists can create medicines that target the fundamental causes of diseases such as genetic abnormalities and cancer. Applications that call for extremely precise interactions with target RNA or DNA, like antisense treatment, RNA interference, and gene editing, are made possible by these customized sequences. Custom oligos are a vital component of personalized medicine, contributing to the advancement of novel medicines that improve patient outcomes by reducing off-target effects and increasing therapeutic efficacy.

The Importance of Personalized Oligos in Biotechnology Particularly in the creation of targeted therapies, Custom Oligonucleotide Synthesis are essential to biotechnology. These brief artificial nucleic acid strands can be precisely engineered to align with the genetic sequences implicated in a range of illnesses. Through the development of tailored oligonucleotides, scientists can produce new therapeutics that target the root reasons of illnesses like cancer, genetic abnormalities, and viral infections. Custom oligos offer unparalleled accuracy in modern medicine by allowing focused medicines that reduce off-target effects and maximize treatment efficacy.

Drug Development's Function in the CDMO

In the drug research procedure, Contract research and Manufacturing Organizations (CDMOs) are crucial collaborators, especially for businesses observing to commercialize novel medicines. The design, synthesis, and production of distinctive oligos and other medicinal substances are just a few of the amenities that are included in CDMO drug development. By offering the required knowledge, tools, and support, these businesses expedite the development process and free up pharmaceutical companies to concentrate on their primary skills. By working together with CDMOs, production may be scaled up effectively and regulatory requirements can be met, resulting in timely patient access to innovative therapies.

Recognizing PPQ Manufacturing

A crucial stage in the medication development lifecycle is Process Performance Qualification (PPQ) manufacturing, which guarantees that the production process continuously yields high-quality goods. The validation of the complete manufacturing process, which includes the synthesis of unique oligos, is the focus of this step. The purpose of PPQ manufacture is to prove that the method can generate pharmaceutical ingredients that adhere to predetermined quality criteria. In order to protect the quality and effectiveness of the finished medicinal products, manufacturers can detect any possible problems and take corrective action by carrying out thorough testing and analysis during this step.

The Process Performance Qualification Protocol: Its Significance

A systematic framework known as the Process Performance Qualification Protocol describes the methods and standards for certifying the manufacturing process. This procedure is necessary to guarantee that every step of the production process—from choosing raw materials to testing the finished product—is carefully considered. Manufacturers can show the dependability of their manufacturing processes and assure regulatory compliance by following the Process Performance Qualification Protocol. This attention to detail is especially crucial when producing bespoke oligos, since successful medicinal applications depend heavily on accuracy and quality.

[inscinstech]

Advancements in Oligonucleotide Synthesis and DNA Synthesizers

Oligonucleotide synthesis is a fundamental process in molecular biology involving the creation of short DNA or RNA sequences. These oligonucleotides serve as primers, probes, and therapeutic agents, playing critical roles in genetic research and biotechnology. The ability to synthesize specific sequences has revolutionized genetic engineering and diagnostics. Advances in this field have led to the development of more efficient and accurate synthesis techniques.

The Process of Oligonucleotide Synthesis

Synthesis involves sequentially adding nucleotides to a growing chain, following a predetermined sequence. This process is typically automated and carried out on solid supports, ensuring high accuracy and efficiency. The synthesis of oligonucleotides has become faster and more reliable with advances in technology. Researchers can now produce longer sequences with fewer errors, enhancing the scope of genetic research. The automation of synthesis has also reduced the time and labour required for large-scale production.

Importance of DNA Synthesizers

DNA Synthesizer is specialized instruments designed to automate the synthesis of oligonucleotides. These machines have revolutionized the field by significantly reducing the time and labour required for synthesis. Modern DNA synthesizers offer high throughput, enabling the production of numerous oligonucleotides simultaneously. This efficiency is crucial for high-demand applications such as genomic research and therapeutic development. The precision and reliability of these instruments are essential for ensuring the accuracy of synthesized sequences.

Applications of Oligonucleotide Synthesis

Oligonucleotide synthesis have a wide range of applications, from basic research to clinical diagnostics and therapeutics. They are essential for polymerase chain reactions (PCR), DNA sequencing, and gene editing. In therapeutics, synthetic oligonucleotides are used in antisense therapies and RNA interference (RNAi) technologies. These applications are driving advances in personalized medicine and genetic therapies. The versatility of oligonucleotides makes them invaluable tools in both research and clinical settings.

Innovations in DNA Synthesizers

Recent advancements in DNA synthesizers have focused on increasing the efficiency and accuracy of synthesis. These innovations include improved reagents, automated error-checking, and integration with bioinformatics tools. As a result, researchers can now synthesize longer and more complex sequences with greater confidence. The integration of advanced technologies has streamlined the synthesis process, reducing costs and increasing accessibility. These innovations are paving the way for new discoveries and applications in molecular biology.

Conclusion

Oligonucleotide synthesis and DNA synthesizers have transformed molecular biology and biotechnology. The ability to quickly and accurately synthesize custom DNA sequences has opened up new possibilities for research and therapeutic applications. As technology continues to advance, the impact of these tools will only grow. For the latest in DNA synthesis technology, visit inscinstech.com.cn.

Blog Source URL :

[polarisoligos]

Unlocking Genetic Innovation: The Power of Long DNA and RNA Oligo Synthesis

Long RNA Oligo synthesis is vital to unlocking this potential. Scientists can develop novel therapeutics that target specific genes or proteins by synthesizing long RNA sequences. For example, antisense oligonucleotides (ASOs) are short, synthetic strands of RNA designed to bind to specific mRNA molecules, blocking their translation into proteins. Long RNA Oligo synthesis allows for the creation ASOs that are long enough to target complex regions of the mRNA, increasing their specificity and effectiveness.

[industrynewsupdates]

Oligonucleotide Synthesis Market Analysis And Segment Forecast 2024-2030

The global oligonucleotide synthesis market size was estimated at USD 3.68 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 13.21% from 2024 to 2030. 

The decreasing prices of sequencing have led to increasing demand for custom-made nucleotides for applications across genetic testing, research, forensics applications, and drug development. This has further boosted the demand for oligonucleotide synthesis. The COVID-19 pandemic has affected every market globally and there has been a surge in the demand for efficient treatment against COVID-19.

Gather more insights about the market drivers, restrains and growth of the Oligonucleotide Synthesis Market

Oligonucleotide therapeutics hold immense potential for treating chronic conditions such as cardiovascular diseases, cancers, and retinal disorders. Emerging new applications of oligo sequences in multiple fields of biotechnology are expected to increase market growth. Demand for molecular diagnostics in precision care is an important emerging application field for oligonucleotide synthesis.

The introduction of advanced techniques such as CRISPR and high-throughput sequencing for gene expression analysis has simplified the genetic screening and modification of genomes. Such innovations are observed to influence the demand for oligonucleotide synthesis. Manufacturers invest in technology development to enable the production of long Oligonucleotides with higher precision and better yield to cater to the growing need for custom oligos.

The availability of a regulatory environment that supports the progress of genomics is the key factor contributing to the market growth. Changes in the regulatory policies to provide a well-framed environment for advanced biological research and application in human use are expected to influence demand for oligonucleotide synthesis significantly. Stem cells, regenerative medicine, genetic engineering, and synthetic biology are the prominent fields identified with high potential in healthcare. For instance, the International Society for Stem Cell Research (ISSCR) ethics and public policy committee aims to recognize and resolve issues by conducting open discussions. The committee includes experts in ethics, law, and social policy worldwide.

Oligonucleotide Synthesis Market Segmentation

Grand View Research has segmented the global oligonucleotide synthesis market report based on product & service, application, and region:

Product & Service Outlook (Revenue, USD Million, 2018 - 2030)

• Oligonucleotides

o DNA

o Column-based

o Array-based

o RNA

o By Technology

o Column-based

o Array-based

o By Type

o Short RNA Oligos (<65 nt)

o Long RNA Oligos (>65 nt)

o CRISPR (sgRNA)

• Equipment/Synthesizer

• Reagents

• Services

o DNA

o Custom Oligo Synthesis Services

o 25 nmol

o 50 nmol

o 200 nmol

o 1000 nmol

o 10000 nmol

o Modification Services

o Purification Services

o RNA

o Custom Oligo Synthesis Services

o 25 nmol

o 100 nmol

o 1000 nmol

o 10000 nmol

o Modification Services

o Purification Services

Application Outlook (Revenue, USD Million, 2018 - 2030)

• PCR Primers

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• PCR Assays & Panels

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• Sequencing

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• DNA Microarrays

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• Fluorescence In Situ Hybridization (FISH)

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• Antisense Oligonucleotides

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• Other Applications

Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o Germany

o U.K.

o France

o Spain

o Italy

o Denmark

o Sweden

o Norway

• Asia Pacific

o China

o Japan

o India

o South Korea

o Australia

o Thailand

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa (MEA)

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global optical genome mapping market size was valued at USD 104.1 million in 2023 and is expected to grow at a CAGR of 26.76% from 2024 to 2030. 

• The global therapeutic drug monitoring market size was valued USD 1.80 billion in 2023 and is projected to grow at a CAGR of 3.8% from 2024 to 2030. 

Key Companies & Market Share Insights

Some of the key players operating in the market include Merck KGaA, Thermo Fisher Scientific, Inc., and Agilent Technologies. These players focus on business strategies such as partnerships/collaborations, product launches, and expansion. Twist Bioscience, Biolegio, and LGC Biosearch Technologies are some of the emerging market participants in the oligonucleotide market. These players primarily focus on expansion and partnerships to strengthen their position in the market.

Key Oligonucleotide Synthesis Companies:

• Thermo Fisher Scientific, Inc.

• Merck KGaA

• Danaher Corporation

• Dharmacon Inc.

• Agilent Technologies

• Bio-synthesis

• Kaneka Eurogentec S.A

• LGC Biosearch Technologies

• Biolegio

• Twist Bioscience

Recent Developments

• In October 2023, IDT inaugurated a new therapeutic manufacturing facility to meet the increasing demand in genomic medicine. The new facility is equipped to support the production of therapeutic oligonucleotides, catering to the expanding needs in the field of genomics and personalized medicine.

• In September 2023, Danaher Corporation (Integrated DNA Technologies) introduced a range of xGen NGS products tailored for the Ultima Genomics UG 100TM platform. The suite includes adapters, primers, and universal blockers, catering to various applications such as DNA, RNA, & methylation sequencing workflows. This offering is complemented by IDT's proven hybridization capture chemistry, enhancing versatility for researchers.

• In July 2023, Analytix introduced two new instruments designed for organic synthesis, including wavePREP, tailored for oligonucleotide synthesis, and Xelsius, a workstation for multireaction synthesis.

• In May 2023, GenScript expanded its life sciences facility in Zhenjiang, Jiangsu, China, to offer a rapid, high-purity oligonucleotide and peptide synthesis service tailored for research & development as well as preclinical applications.

• In May 2023, Twist Bioscience and CeGaT GmbH launched the Twist Alliance CeGaT RNA Fusion Panel. This collaborative effort aims to provide a specialized tool for oncology research, facilitating the detection of RNA fusions and enabling transcript variant analysis. RNA fusions, a result of chromosomal arrangements often seen in cancers, can now be efficiently studied using this newly introduced panel.

• In February 2023, Fluor Corp. and Agilent Technologies, Inc. collaborated to enhance its oligonucleotide therapeutics manufacturing facility in Frederick, Colorado. Under this collaboration, Fluor is expected to support the project's engineering and procurement. The total value of the project is evaluated at USD 725 million.

Order a free sample PDF of the Oligonucleotide Synthesis Market Intelligence Study, published by Grand View Research.

[mysticalpeacenut]

Trends in RNA Targeted Drug Development

RNA has emerged as a promising target within the subject of drug discovery, supplying new opportunities for healing intervention in a number sicknesses. Unlike traditional approaches that mainly recognition on proteins, RNA-targeted drug development seeks to govern RNA molecules immediately, influencing gene expression and protein synthesis in ways that have been previously inconceivable. This shift is opening up interesting avenues for the remedy of genetic disorders, cancers, and viral infections, among others.

In this weblog, we're going to explore the ultra-modern developments in RNA-targeted drug development and the way this innovative approach is reworking the landscape of medication.

The Rise of RNA-Targeted Drug Discovery

RNA Targeted Drug Discovery has won widespread momentum in recent years, driven by means of advances in information RNA biology and the improvement of new technologies. Traditional drug discovery has predominantly targeted on proteins as the primary targets for healing intervention. However, RNA offers several unique benefits as a drug target.

Firstly, RNA plays a valuable role inside the waft of genetic statistics, appearing as a crucial intermediary among DNA and proteins. By focused on RNA, researchers can immediately impact gene expression, doubtlessly silencing dangerous genes or correcting genetic defects. This makes RNA-focused treatment options in particular attractive for treating genetic sicknesses wherein traditional protein-targeting procedures may also fall quick.

Moreover, the invention of various RNA sorts, which include long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), has multiplied the scope of RNA-targeted drug discovery. These RNA molecules play important roles in gene law and cell processes, and concentrated on them can provide new therapeutic avenues.

Transforming RNA-Targeted Drug Discovery

The transformation of RNA-targeted drug discovery has been fueled through numerous key traits:

RNA Interference (RNAi): RNAi is a groundbreaking generation that permits for the selective silencing of particular genes. By introducing small interfering RNAs (siRNAs) into cells, researchers can degrade goal RNA molecules, efficiently shutting down the expression of sickness-causing genes. RNAi has already brought about the development of numerous FDA-authorised tablets, demonstrating the potential of RNA-focused healing procedures.

Antisense Oligonucleotides (ASOs): ASOs are short, artificial RNA-like molecules designed to bind to particular RNA sequences. By binding to goal RNA, ASOs can modulate splicing, degrade RNA, or block translation, presenting a versatile technique to RNA-targeted drug development. ASOs have shown promise in treating a number of situations, which includes spinal muscular atrophy and Duchenne muscular dystrophy.

Drugs Targeting RNA Riboswitches: RNA riboswitches are regulatory segments of RNA which can trade their shape in reaction to small molecule binding. These riboswitches manage gene expression by means of influencing RNA transcription, translation, or balance. Drugs focused on RNA riboswitches represent a novel method to modulate gene expression and provide a new frontier in RNA drug improvement.

CRISPR-Cas Systems: Originally advanced as a tool for gene modifying, CRISPR-Cas structures are actually being tailored for RNA targeting. CRISPR-based technology may be used to precisely edit RNA molecules, providing a effective tool for correcting genetic defects or modulating gene expression. This method has the capability to revolutionize RNA-centered drug discovery via enabling unique, on-demand manipulation of RNA.

RNA Vaccines: The fulfillment of mRNA vaccines in combating COVID-19 has underscored the ability of RNA-primarily based cures. MRNA vaccines paintings by using introducing synthetic mRNA into cells, teaching them to provide particular proteins that elicit an immune reaction. This technique may be extended to other diseases, doubtlessly leading to the development of vaccines and therapies for a wide variety of situations.

The Future of RNA-Targeted Drug Development

The destiny of RNA-focused drug improvement is highly promising, with ongoing research aimed at overcoming present challenges and expanding the range of treatable situations. Key regions of focus consist of enhancing the stability and delivery of RNA-primarily based drugs, lowering off-goal consequences, and exploring new RNA targets.

One of the most interesting regions of studies involves RNA riboswitches and different regulatory RNA elements. By designing tablets that especially bind to those RNA structures, researchers can modulate gene expression in a especially managed way. This technique has the potential to liberate new healing techniques for situations that are currently hard to deal with.

Another trend is the exploration of RNA modifications, inclusive of methylation, that may affect RNA characteristic. By focused on these changes, researchers can expand remedies that pleasant-tune RNA pastime, offering a new stage of precision in drug development.

In addition to therapeutic applications, RNA-focused techniques are being explored for diagnostic purposes. RNA biomarkers are being investigated as capability tools for early sickness detection and tracking remedy responses. This should lead to the development of customized medication techniques which can be tailored to an man or woman’s RNA profile.

Conclusion

The rapid improvements in RNA-targeted drug discovery and RNA-targeted drug improvement are reworking the panorama of medication. From RNAi and antisense oligonucleotides to CRISPR-Cas structures and RNA vaccines, the opportunities for therapeutic intervention are increasing at an extraordinary fee. The potential to target RNA at once gives new possibilities for treating a wide variety of diseases, from genetic problems to cancer.

As researchers maintain to explore the ability of RNA-primarily based treatment options, the future of drugs seems more and more promising. The improvements in RNA drug discovery are paving the manner for a brand new generation of precision remedy, in which treatments may be tailored to the precise molecular makeup of every affected person.

For those at the forefront of this interesting area, the possibilities are endless. Whether you’re involved in research, development, or clinical utility, staying knowledgeable approximately the contemporary traits in RNA-centered drug discovery is important for riding innovation and enhancing affected person outcomes.

At Depixus, we are devoted to advancing the sphere of RNA-targeted drug discovery. Our current technologies are designed to aid researchers of their quest to increase the following generation of RNA-based totally healing procedures.

To learn more about how we can help you live in advance in this hastily evolving area, go to us at Depixus.

Reposted Blog Post URL: https://petrickzagblogger.wordpress.com/2024/08/28/rna-targeted-drug-development/

[rnomics]

IJMS, Vol. 25, Pages 9010: Sepsis Biomarkers: Advancements and Clinical Applications—A Narrative Review

Sepsis is now defined as a life-threatening syndrome of organ dysfunction triggered by a dysregulated host response to infection, posing significant challenges in critical care. The main objective of this review is to evaluate the potential of emerging biomarkers for early diagnosis and accurate prognosis in sepsis management, which are pivotal for enhancing patient outcomes. Despite advances in supportive care, traditional biomarkers like C-reactive protein and procalcitonin have limitations, and recent studies have identified novel biomarkers with increased sensitivity and specificity, including circular #RNAs, HOXA distal transcript antisense #RNA, #microRNA-486-5p, protein C, triiodothyronine, and prokineticin 2. These emerging biomarkers hold promising potential for the early detection and prognostication of sepsis. They play a crucial role not only in diagnosis but also in guiding antibiotic therapy and evaluating treatment effectiveness. The introduction of point-of-care testing technologies has brought about a paradigm shift in biomarker application, enabling swift and real-time patient evaluation. Despite these advancements, challenges persist, notably concerning biomarker variability and the lack of standardized thresholds. This review summarizes the latest advancements in sepsis biomarker research, spotlighting the progress and clinical implications. It emphasizes the significance of multi-biomarker strategies and the feasibility of personalized medicine in sepsis management. Further verification of biomarkers on a large scale and their integration into clinical practice are advocated to maximize their efficacy in future sepsis treatment. https://www.mdpi.com/1422-0067/25/16/9010?utm_source=dlvr.it&utm_medium=tumblr

[poonamcmi]

Oligonucleotide Synthesis Market is Expected to Witness High Growth Owing to Rising Biotechnology Research and Development

The oligonucleotide synthesis market involves the production of shorter sequences of nucleic acids known as oligonucleotides that are widely used in research, diagnostics and therapeutics applications. Oligonucleotides play a vital role in gene expression studies, next-generation sequencing, DNA & RNA analysis, qPCR and molecular diagnostics. The increasing focus on biotechnology research especially in life sciences and genomics has boosted the demand for specialized oligonucleotides.

The Global oligonucleotide synthesis market is estimated to be valued at US$ 4565 Bn in 2024 and is expected to exhibit a CAGR of 13% over the forecast period of 2024 to 2031.

Key Takeaways Key players operating in the oligonucleotide synthesis are Forte Research Systems (India), ICON plc (Ireland), Merge healthcare incorporated (U.S.), Bio-Optronics (U.S.), DSG INC (U.S.), ArisGlobal (India), ERT Clinical Bioclinica (U.S.), Oracle Corporation (U.S.), Medidata Solutions (U.S.), DATATRAK International, Inc. (U.S.), and MedNet Solutions, Inc., (U.S.) among others. These key players are focusing on partnerships and new technology development to expand their oligonucleotide synthesis capabilities.

Key Oligonucleotide Synthesis Market Demand include increasing research in personalized medicine and precision genomics. Additionally, the growing pipeline of oligo-based drugs and clinical trials for rare diseases will provide momentum.

With regards to geographical expansion, North America dominates the global oligonucleotide synthesis market followed by Europe. However, Asia Pacific is expected to witness highest growth rate owing to increasing government support for biotech sector and growing industry investments in China and India.

Market Drivers Increasing R&D expenditure for biotechnology research especially in life sciences and biopharmaceutical industry is a key factor contributing to the Oligonucleotide Synthesis Market Size And Trends Oligonucleotides play a vital role in new drug discovery and development which is propelling many biotech companies to adopt oligo synthesis. Rising applications of oligos in development of advanced therapeutics like antisense oligonucleotides and siRNA is expected to drive the market during the forecast period.

PEST Analysis Political: Government regulations around drug research and development have an impact. Changes in healthcare policies and funding also affect the market. Economic: The state of the economy influences research spending by pharmaceutical companies and academic institutions, affecting demand. Rising healthcare costs drive need for new drug therapies. Social: An aging global population with increased prevalence of diseases like cancer is leading to higher demand for advanced drug development and diagnostic tools. Social attitudes around health and biotech also evolve over time.

Technological: Advancements in DNA sequencing, synthesis and analysis technologies enable new applications and drive down costs, expanding the potential market. Automation and artificial intelligence are enhancing R&D productivity.

North America holds the largest share in terms of value currently due to heavy spending on drug R&D by major players in the US and Canada. However, Asia Pacific is expected to grow at the fastest rate during the forecast period as the pharmaceutical industry expands rapidly in major emerging economies like China and India. These countries are making large investments in research and increasing regulatory approvals are also supporting market growth.

Europe accounts for a sizable share as well owing to extensive government funding for research programs. However, the high costs of oligonucleotide therapies has limited their use thus far. If pricing and reimbursement improve in the future, the European market could witness stronger growth. On the other hand, the Middle East and Africa region is relatively nascent but demand may rise over time with economic development across various nations. Get More Insights On, Oligonucleotide Synthesis Market About Author: Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, c

[businessindustry]

Antisense Oligonucleotides Market Key Players Profile Share and Growth by 2032

The Reports and Insights, a leading market research company, has recently releases report titled “Antisense Oligonucleotides Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global Antisense Oligonucleotides Market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights:

How big is the Antisense Oligonucleotides Market?

The global antisense oligonucleotides market size reached US$ 2.8 billion in 2023. Looking forward, Reports and Insights expects the market to reach US$ 4.9 billion in 2032, exhibiting a growth rate (CAGR) of 6.5% during 2024-2032.

What are Antisense Oligonucleotides?                                                                                                                                                                            

Antisense oligonucleotides (ASOs) are short, synthetic nucleic acid strands designed to bind specifically to messenger RNA (mRNA) molecules, thereby regulating gene expression. By attaching to their target mRNA, ASOs can inhibit the production of disease-causing proteins, degrade the mRNA, or alter splicing patterns. This targeted approach allows for precise treatment of genetic disorders, viral infections, and some cancers. ASOs are a promising therapeutic strategy due to their specificity, ability to target previously "undruggable" genes, and advancements in their design and delivery.

Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2216

What are the growth prospects and trends in the Antisense Oligonucleotides industry?

The antisense oligonucleotides (ASOs) market growth is driven by various factors and trends. The antisense oligonucleotides (ASOs) market is expanding quickly due to their potential in treating various genetic disorders, cancers, and viral infections. Growth is fueled by advancements in biotechnology, increased investment in research and development, and a rising number of FDA approvals for ASO-based therapies. North America currently dominates the market due to its robust biopharmaceutical sector and supportive regulatory environment, with significant growth also seen in Europe and Asia-Pacific. Key market players are focusing on strategic collaborations and innovations to improve the efficacy, safety, and delivery of ASO therapies, thereby broadening their therapeutic applications and market presence. Hence, all these factors contribute to antisense oligonucleotides (ASOs) market growth.

What is included in market segmentation?

The report has segmented the market into the following categories:

By Therapeutic Areas

Genetic Disorders

Duchenne Muscular Dystrophy (DMD)

Spinal Muscular Atrophy (SMA)

Familial Hypercholesterolemia

Others

Oncology

Neurological Disorders

Amyotrophic Lateral Sclerosis (ALS)

Acquired Immunodeficiency Syndrome (AIDS)

Others

Cardiovascular Diseases

Ophthalmic

Cytomegalovirus Retinitis

Others

Infectious Diseases

Others

By End-User

Hospitals and Clinics

Pharmaceutical and Biotechnology Companies

Research Institutes and Academic Centers

Others

North America

United States

Canada

Europe

Germany

United Kingdom

France

Italy

Spain

Russia

Poland

Benelux

Nordic

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

ASEAN

Australia New Zealand

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Middle East Africa

Saudi Arabia

South Africa

United Arab Emirates

Israel

Rest of MEA

Who are the key players operating in the industry?

The report covers the major market players including:

Ionis Pharmaceuticals, Inc.

Sarepta Therapeutics, Inc.

Biogen

Isarna Therapeutics GmbH

Enzon Pharmaceuticals, Inc.

Bio-Path Holdings, Inc.

Gene Signal International SA

GlaxoSmithKline plc

miRagen Therapeutics, Inc.

Regulus Therapeutics

Rexahn Pharmaceuticals, Inc.

View Full Report: https://www.reportsandinsights.com/report/Antisense Oligonucleotides-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: sales@reportsandinsights.com Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1

[credenceresearchdotblog]

Global amyloidosis therapeutic treatment market is expected to develop at a compound annual growth rate (CAGR) of 7.60%, from its estimated USD 2251.2 million in 2023 to USD 4352.35 million in 2032.Amyloidosis is a rare and complex group of diseases characterized by the abnormal accumulation of amyloid proteins in tissues and organs. These proteins can lead to severe organ damage and potentially life-threatening complications. The therapeutic treatment market for amyloidosis is evolving rapidly, driven by advancements in medical research, the development of new drugs, and increasing awareness of this challenging condition.

Browse the full report at https://www.credenceresearch.com/report/amyloidosis-therapeutic-treatment-market

Market Overview

The global amyloidosis therapeutic treatment market is experiencing significant growth, fueled by a combination of rising incidence rates, expanding research initiatives, and increasing healthcare expenditures. The market encompasses a range of therapeutic options, including pharmacological treatments, supportive therapies, and emerging novel therapies.

Pharmacological Treatments

Pharmacological treatment options for amyloidosis primarily target the underlying cause of the disease or aim to alleviate symptoms. The market is currently dominated by drugs that target the specific types of amyloidosis:

1. AL Amyloidosis: This form of amyloidosis results from abnormal immunoglobulin light chains and is often associated with multiple myeloma. The treatment approach involves managing the underlying plasma cell disorder. Therapies include proteasome inhibitors such as Bortezomib and Carfilzomib, immunomodulatory drugs like Lenalidomide, and monoclonal antibodies such as Daratumumab. These drugs have shown efficacy in reducing the production of amyloidogenic light chains and improving patient outcomes.

2. ATTR Amyloidosis: Caused by the accumulation of transthyretin protein, ATTR amyloidosis is further classified into hereditary (hATTR) and wild-type (wtATTR) forms. The therapeutic landscape includes: - Tafamidis: This drug stabilizes the transthyretin protein, preventing its misfolding and aggregation. Tafamidis has demonstrated significant benefits in slowing disease progression and improving quality of life for patients with ATTR amyloidosis. - Diflunisal: An older non-steroidal anti-inflammatory drug, Diflunisal has been repurposed for ATTR amyloidosis treatment due to its ability to stabilize transthyretin. - Gene Silencing Therapies: Emerging treatments such as Patisiran and Inotersen use RNA interference and antisense oligonucleotides to reduce the production of transthyretin. These therapies have shown promise in clinical trials and represent a significant advancement in the treatment of ATTR amyloidosis.

Supportive Therapies

Supportive therapies play a crucial role in managing the symptoms and complications of amyloidosis. These include symptomatic management of heart failure, renal impairment, and neuropathy. For instance, diuretics and antihypertensive agents are commonly used to manage cardiac amyloidosis, while dialysis may be required for patients with renal involvement. Pain management and physical therapy are also essential for addressing neuropathic symptoms.

Emerging Therapies and Research

The amyloidosis therapeutic treatment market is witnessing a surge in research and development activities aimed at discovering innovative treatments. Key areas of focus include:

1. Monoclonal Antibodies: Researchers are exploring the use of monoclonal antibodies targeting amyloid deposits directly or modulating the immune system to enhance amyloid clearance.

2. Small Molecules: New small molecules are being developed to disrupt amyloid fibril formation or promote the disaggregation of existing fibrils. These compounds have the potential to offer new treatment options for various forms of amyloidosis.

3. Gene Therapy: Advances in gene therapy hold promise for addressing the genetic basis of hereditary amyloidosis. By correcting or replacing faulty genes, these therapies could potentially prevent or cure the disease.

Challenges and Opportunities

Despite the progress in amyloidosis treatment, several challenges remain. The rarity of the disease can lead to difficulties in diagnosis and treatment, and the high cost of innovative therapies can be a barrier to access for many patients. Additionally, the complexity of amyloidosis requires a multidisciplinary approach to manage the diverse manifestations of the disease effectively.

However, the growing investment in research and development, coupled with advancements in personalized medicine, presents significant opportunities for improving patient outcomes. Continued innovation and collaboration among researchers, healthcare providers, and pharmaceutical companies are essential to overcoming these challenges and advancing the treatment landscape for amyloidosis.

Key Players

Prothena Corporation Plc.

Eidos Therapeutics

Pfizer Inc.

SOM Biotech

Corino Therapeutics

Johnson and Johnson Services, Inc.

AstraZeneca Plc.

Alnylam Pharmaceuticals, Inc.

GlaxoSmithKline, Plc.

Others

Segmentation

By Type of Amyloidosis

AL Amyloidosis (Primary Amyloidosis)

ATTR Amyloidosis (Hereditary and Wild-Type)

AA Amyloidosis (Secondary Amyloidosis)

By Treatment Modalities

Chemotherapy

Immunomodulatory Drugs (IMiDs)

Monoclonal Antibodies

TTR Stabilizers

RNA Interference (RNAi) Therapies

Liver Transplantation

Supportive Care

By Disease Severity

Newly Diagnosed Patients

Relapsed or Refractory Disease

Advanced Disease

By Region

North America

The U.S.

Canada

Mexico

Europe

Germany

France

The U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/amyloidosis-therapeutic-treatment-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[simranmakhija1]

Addressing Challenges in Oligonucleotide Synthesis: Quality, Scale, and Efficiency

The Oligonucleotide Synthesis Market is experiencing rapid growth driven by advancements in genomics, personalized medicine, and molecular diagnostics. Oligonucleotides, short sequences of nucleotides, are essential tools in various applications, including DNA sequencing, gene editing, PCR amplification, and RNA interference. The increasing demand for custom oligonucleotides for research, diagnostic, and therapeutic purposes is fueling the expansion of the oligonucleotide synthesis market.

Get a free Sample: https://www.marketdigits.com/request/sample/4550 

One of the key drivers of market growth is the rising adoption of oligonucleotide-based therapies, such as antisense oligonucleotides (ASOs), siRNAs, and aptamers, for the treatment of genetic disorders, cancer, and infectious diseases. Oligonucleotide therapeutics offer targeted and specific modes of action, allowing for precision medicine approaches and reduced off-target effects compared to traditional small molecule drugs. As a result, pharmaceutical companies and biotech firms are investing heavily in oligonucleotide drug discovery and development, driving the demand for high-quality oligonucleotide synthesis services.

The Oligonucleotide Synthesis Market is Valued USD 8.4 billion in 2024 and projected to reach USD 22.9 billion by 2030, growing at a CAGR of CAGR of 15.5% During the Forecast period of 2024-2032.

In addition to therapeutics, oligonucleotides are widely used in research and diagnostics for studying gene expression, identifying genetic mutations, and detecting infectious agents. The growing demand for personalized medicine and companion diagnostics is driving the need for custom oligonucleotide probes and primers tailored to individual patient profiles. Furthermore, advancements in next-generation sequencing (NGS) technologies and gene editing tools, such as CRISPR-Cas9, are driving the demand for high-throughput oligonucleotide synthesis platforms capable of producing large quantities of oligos with high purity and fidelity.

Major vendors in the global Oligonucleotide Synthesis market are Agilent Technologies, Inc., Biolegio, Biolytic Lab Performance Inc., Bio-Synthesis Inc., Cytiva, DH Life Sciences, LLC., GENERI BIOTECH, Horizon Discovery Ltd., Kaneka Eurogentec S.A, LGC Limited, Maravai LifeSciences, Thermo Fisher Scientific Inc., Twist Bioscience.,  and Others.

The oligonucleotide synthesis market is characterized by the presence of both established players and emerging startups offering a wide range of synthesis platforms and services. Major players in the market include Integrated DNA Technologies, Inc. (IDT), Merck KGaA, Thermo Fisher Scientific Inc., Eurofins Scientific SE, and Bio-Synthesis, Inc., among others. These companies provide custom oligonucleotide synthesis services, as well as a variety of oligo modifications, purification methods, and quality control assays to meet the diverse needs of researchers and clinicians.

Emerging trends in the oligonucleotide synthesis market include the development of novel synthesis chemistries, automation technologies, and digital solutions for designing and ordering custom oligos. Continuous innovation in oligonucleotide synthesis platforms, such as microarray-based synthesis, solid-phase synthesis, and enzymatic synthesis, is driving improvements in oligo yield, length, and quality, enabling new applications in synthetic biology, nanotechnology, and drug delivery.

Looking ahead, the oligonucleotide synthesis market is poised for further expansion driven by advancements in gene therapy, nucleic acid-based vaccines, and precision diagnostics. As the field of genomics continues to evolve, the demand for custom oligonucleotide synthesis services will continue to grow, offering new opportunities for market players to innovate and collaborate in addressing unmet needs in healthcare and life sciences research.

[veliterbio]

What Makes an RNA Synthesis Company Vital for Biotech Innovation?

The tailored RNA molecules obligatory for cutting-edge investigation and pharmaceutical development are provided by RNA synthesis businesses, which are energetic for biotech innovation. These businesses have the expertise to generate customized RNA oligonucleotides, which are vital for RNA interference, gene therapy, and vaccine development. These companies help researchers to follow novel directions in genetics and generate groundbreaking therapies by assuring accurate and good RNA production. They are vital collaborators in the advancement of biotechnology since of their capacity to create customized RNA sequences, which speeds up the development and application of novel biotechnologies.

The Biotechnology of RNA Oligo Synthesis: Its Significance An essential biotechnology process that lays the groundwork for a diversity of scientific and medical applications is RNA oligo production. Investigators can study gene function, control gene expression, and make new treatments by using RNA oligonucleotides, which are small sequences of RNA that are generated to meet specific necessities. For approaches like gene editing, mRNA vaccinations, and RNA interference (RNAi), where exact RNA sequences are required to produce the desired consequences, RNA oligo production is vital. To advance these fields and spur biotechnology innovation, it is important to be able to generate bespoke RNA oligos by great precision and purity.

Research and Development: The Function of an RNA Synthesis Company

In the study and creation of cutting-edge biotechnologies, an RNA synthesis company is essential. These businesses provide specialized RNA oligonucleotide manufacturing services, giving researchers the resources they require to conduct studies and create novel therapeutic interventions. Scientists can conduct tests with confidence in the correctness and dependability of their materials when an RNA synthesis firm provides them with high-quality, customized RNA sequences. Gene treatments, vaccinations, and other RNA-based technologies that are revolutionizing the biotechnology industry depend on this assistance to advance.

Modern Medicine's Reaction to Oligonucleotide Drugs

Therapeutics recognized as oligonucleotide medicines are a fast expanding class that offer novel approaches to giving a range of illnesses. These medications, which include aptamers, siRNA, and antisense oligonucleotides, function by exactly modifying and targeting certain gene expression. Treatments for viral infections, malignancies, and genetic diseases have all showed promise by oligonucleotide medicines. Custom oligonucleotide synthesis is a precarious component of drug research since it proposals the RNA or DNA sequences required for therapeutic design and testing.

The Technique of Manufacturing Drug Substances for Oligonucleotides

To promise the creation of safe and effective therapeutic agents, the drug substance manufacturing procedure for oligonucleotides is intricate and deeply controlled. The oligonucleotide drug material is synthesized in this technique, and then it is cleansed, formulated, and subjected to severe quality control testing. Strict regulatory necessities must be encountered during the manufacturing procedure to guarantee that the finished product is pure, consistent, and suitable for clinical usage. In order to safeguard that these cutting-edge treatments fulfill the vital standards for quality and safety, businesses that specialize in the production of oligonucleotide drug substances are vital to their commercialization.

The Use of Personalized Oligonucleotide Synthesis in the Development of Therapeutics

Particularly for disorders where there are specific genetic targets, custom oligonucleotide synthesis is precious in the creation of novel therapeutics. Through this method, oligonucleotides that are specifically tailored to meet the necessities of each therapeutic application can be designed and produced. The precise RNA or DNA sequences needed for experimental medications must be created via custom synthesis in order for researchers to evaluate and improve their treatment strategies. Personalized medicine and other cutting-edge therapeutic approaches are made possible by the flexibility and accuracy provided by custom oligonucleotide synthesis in the development of targeted medicines.

[inscinstech]

Bridging the Frontiers of Science: Oligonucleotide Synthesis and Protein Purification

Imagine the potential of manipulating genetic sequences with pinpoint accuracy or isolating a single protein from a myriad of cellular components. These feats, once considered science fiction, are now commonplace in modern laboratories, thanks to advancements in oligonucleotide synthesis and protein purification. These technologies are fundamental to biochemistry and molecular biology, driving innovations in medical research, diagnostics, and therapeutics.

The Science of Oligonucleotide Synthesis

Oligonucleotide synthesis involves creating short sequences of nucleotides, the building blocks of DNA and RNA. These synthetic oligonucleotides are essential tools in genetic research, diagnostics, and therapeutics. By designing specific sequences, scientists can study gene function, develop genetic tests, and create treatments for various diseases.

The process of oligonucleotide synthesis typically involves automated synthesizers that assemble nucleotides in a predetermined order. Each nucleotide is added step-by-step, and the growing chain is protected chemically to prevent unwanted reactions. Once the sequence is complete, the protecting groups are removed, and the oligonucleotide is purified. This high-precision process ensures that the oligonucleotides are accurate and effective for their intended applications.

Applications and Significance of Oligonucleotide Synthesis

The applications of oligonucleotide synthesis are vast and impactful. In research, synthetic oligonucleotides are used in PCR (polymerase chain reaction) to amplify DNA sequences, enabling detailed genetic studies. They are also employed in the development of probes and primers for detecting specific genetic markers associated with diseases. In therapeutics, antisense oligonucleotides can target and modulate gene expression, offering potential treatments for genetic disorders and cancers.

The ability to synthesize oligonucleotides with high accuracy and specificity has revolutionized molecular biology. It allows scientists to explore genetic mechanisms at a granular level, facilitating breakthroughs in understanding disease pathways and developing targeted therapies. The precision of oligonucleotide synthesis is crucial for the success of these applications, underscoring its importance in modern science.

The Art of Protein Purification

Protein purification is the process of isolating a single type of protein from a complex mixture, such as a cell lysate. This process is essential for studying protein structure and function, which are fundamental to virtually every biological process. Purified proteins are used in a wide range of applications, including enzymatic assays, structural biology, and the development of therapeutics.

Applications and Significance of Protein Purification

The ability to isolate pure proteins is crucial for scientific progress. Researchers can study the protein’s role in cellular processes, its interactions with other molecules, and its potential as a drug target. Without protein purification, it would be nearly impossible to conduct these detailed analyses. Purified proteins are also essential for pharmaceutical manufacturing, ensuring that medicines are safe and effective.

In structural biology, purified proteins are used to determine the three-dimensional structures of proteins and protein complexes. This information is vital for understanding how proteins function at a molecular level and for designing drugs that can modulate their activity. In enzymology, purified proteins are used to study enzyme kinetics and mechanisms, providing insights into how enzymes catalyze biochemical reactions. The precision and reliability of protein purification are crucial for these applications, highlighting its importance in research and industry.

Integrating Oligonucleotide Synthesis and Protein Purification

The integration of oligonucleotide synthesis and protein purification in a laboratory setting enhances the capability to conduct advanced biotechnological research. For example, synthesized oligonucleotides can be used to clone and express specific proteins, which are then purified for further study. This combination accelerates the pace of research and development, facilitating the creation of new diagnostics and therapeutics.

Future Prospects and Innovations

The future of oligonucleotide synthesis and protein purification looks promising, with ongoing advancements aimed at increasing efficiency, accuracy, and accessibility. Innovations in automation and digital technology are expected to further streamline these processes, making them more user-friendly and cost-effective. As our understanding of genetics and protein chemistry deepens, these technologies will undoubtedly play a crucial role in the next generation of medical and scientific breakthroughs.

Conclusion

For those interested in exploring the latest advancements in oligonucleotide synthesis and protein purification, Inscinstech.com.cn provides a wealth of information and resources. This platform offers detailed insights into the technologies shaping the future of biotechnology, helping researchers and industry professionals stay informed and competitive. By visiting Inscinstech.com.cn, you can gain access to expert knowledge and tools essential for pioneering work in molecular biology and biochemistry.

Blog Source URL :-

[leedsomics]

Long-read transcriptomics of Ostreid herpesvirus 1 uncovers a conserved expression strategy for the capsid maturation module and pinpoints a mechanism for evasion of the ADAR-based antiviral defence

Ostreid herpesvirus 1 (OsHV-1), a member of the family Malacoherpesviridae (order Herpesvirales), is a major pathogen of bivalves. However, the molecular details of the malacoherpesvirus infection cycle and its overall similarity to the replication of mammalian herpesviruses (family Orthoherpesviridae) remain obscure. Here, to gain insights into the OsHV-1 biology, we performed long read sequencing of infected blood clams, Anadara broughtonii, which yielded over one million OsHV-1 long reads. This data enabled the annotation of the viral genome with 78 gene units and 274 transcripts, of which 67 were polycistronic mRNAs, 35 ncRNAs and 20 natural antisense transcripts (NATs). Transcriptomics and proteomics data indicate preferential transcription and independent translation of the capsid scaffold protein as an OsHV-1 capsid maturation protease isoform. The conservation of this transcriptional architecture across Herpesvirales likely indicates its functional importance and ancient origin. Moreover, we traced RNA editing events using short read sequencing and supported the presence of inosine nucleotides in native OsHV-1 RNA, consistent with the activity of ADAR1. Our data suggests that, whereas RNA hyper-editing is concentrated in specific regions of the OsHV-1 genome, single nucleotide editing is more dispersed along OsHV-1 transcripts. In conclusion, we revealed the existence of a conserved pan-Herpesvirales transcriptomic architecture of the capsid maturation module and uncovered a transcription-based viral counter defence mechanism presumably facilitating the evasion of the host ADAR antiviral system. http://dlvr.it/T6PbVc